JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

(2018) Manish R Patel et al.   LANCET ONCOLOGY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

(2017) Joshua Bauml et al.   JOURNAL OF CLINICAL ONCOLOGY

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

(2017) Christopher R Heery et al.   LANCET ONCOLOGY

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

(2017) James L Gulley et al.   LANCET ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

(2016) Kefang Liu et al.   CELL RESEARCH

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab

(2016) Swati Khanna et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study

(2016) Brian O'Sullivan et al.   LANCET ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer

(2016) Hisham Mehanna et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma

(2016) Shrujal S. Baxi et al.   ORAL ONCOLOGY

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

(2016) Rika Fujii et al.   Oncotarget

Immunology and Immunotherapy of Head and Neck Cancer

(2015) Robert L. Ferris   JOURNAL OF CLINICAL ONCOLOGY

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer

(2014) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

(2014) K. Kian Ang et al.   JOURNAL OF CLINICAL ONCOLOGY

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

(2013) Robert Haddad et al.   LANCET ONCOLOGY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study

(2012) M. F. Janssen et al.   QUALITY OF LIFE RESEARCH

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) V. Gregoire et al.   ANNALS OF ONCOLOGY

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis

(2008) Mitchell Machtay et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE